Cargando…
SARS-CoV-2 Infection-Associated Aortic Thrombosis Treated with Oral Factor Xa Inhibition
Coronavirus disease 2019 (COVID-19) is an acute complex systemic disorder caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).While SARS-CoV-2 is known to cause significant pulmonary disease, various extrapulmonary manifestations of COVID-19 have also been reported. Growing ev...
Autores principales: | Strýčková, Alena, Benko, Jakub, Péč, Martin Jozef, Péčová, Monika, Žolková, Jana, Brunclíková, Monika, Bolek, Tomáš, Staško, Ján, Samoš, Matej, Mokáň, Marián |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436625/ https://www.ncbi.nlm.nih.gov/pubmed/36060118 http://dx.doi.org/10.1155/2022/7805900 |
Ejemplares similares
-
The Anti-Thrombotic Effects of PCSK9 Inhibitors
por: Péč, Martin Jozef, et al.
Publicado: (2023) -
Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation
por: Prídavková, Dana, et al.
Publicado: (2019) -
Resistance on the Latest Oral and Intravenous P2Y12 ADP Receptor Blockers in Patients with Acute Coronary Syndromes: Fact or Myth?
por: Blaško, Peter, et al.
Publicado: (2022) -
Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy
por: Benko, Jakub, et al.
Publicado: (2022) -
Does atorvastatin therapy change the anti‐Xa activity in xabans‐treated patients with atrial fibrillation?
por: Škorňová, Ingrid, et al.
Publicado: (2021)